GlassScriptPhysician profile
Jonelle Hudson
NPI 1770175614
$5,803.37
in general payments reported to CMS, 2019-2025
27 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $539 · 2023: $872 · 2024: $2,096 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,142 · Education: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,142.14 |
| Education | $789.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,207.47 | 2023-2025 | Carvykti, Tecvayli, Darzalex |
| Novocure INC. | $970.34 | 2021-2025 | Optune Lua (Novottf-200t), Optune, Optune Gio |
| Daiichi Sankyo INC. | $415.15 | 2021-2025 | Enhertu |
| Seagen INC. | $375.98 | 2022-2023 | |
| Abbvie INC. | $281.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $271.63 | 2024 | Keytruda, Lynparza |
| Incyte Corporation | $263.76 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $263.72 | 2023-2025 | Datroway |
| Myriad Genetic Laboratories, INC. | $255.34 | 2024 | Myrisk |
| Pfizer INC. | $208.28 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $205.52 | 2022-2024 | Reblozyl |
| Glaxosmithkline, LLC. | $203.90 | 2021-2025 | Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $118.99 | 2023 | Imbruvica |
| Celgene Corporation | $112.77 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Exelixis INC. | $110.41 | 2025 | Cabometyx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $105.73 | 2025 | |
| Pharmaessentia USA Corporation | $87.14 | 2025 | Besremi |
| Servier Pharmaceuticals LLC | $75.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $65.62 | 2024-2025 | |
| Genentech USA, INC. | $58.97 | 2024-2025 | Polivy, Tecentriq, Lunsumio |
| Rigel Pharmaceuticals, INC. | $32.33 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $25.50 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.64 | 2025 | Fruzaqla |
| Amgen INC. | $16.90 | 2021 | |
| Puma Biotechnology, INC. | $16.67 | 2024 | |
| Adc Therapeutics America, INC. | $16.23 | 2025 | |
| Astellas Pharma US INC | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonelle Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.